This document outlines BIO's principles on clinical trials.

The U.S. Department of Energy (DOE) and the U.S. Department of Agriculture (USDA) are both strongly committed to expanding the role of biomass as an energy source.

The IES Marine Biotechnology interest group is comprised of educational institutions, research organizations, and private companies.

The report was prepared for the National Commission on Energy Policy (NCEP) by the Role of Biomass in America's Energy Future (RBAEF) project. It asserts that the United States "can replace much of our oil with biofuels - fuels made from plant materials grown by American farmers. These fuels, especially those known as cellulosic biofuels, can be cost-competitive with gasoline and diesel."

Industrial biotechnology is creating new markets for traditional agricultural crops and crop residues as renewable feedstocks, chemical intermediates, and energy sources.

Summaries of plenary sessions, breakout sessions, and workshops at the second annual conference, hosted by BIO, National Agricultural Biotechnology Council, and the American Chemical Society.

Rx Drug Importation Poses Immediate and Incalculable Risk to American Patients (Apr. 19, 2004)

Biotechnology is the use and modification of living organisms or their products for commercial purposes.

The Medicare conference agreement conforms closely to BIO's principles, and the association urges Congress to act quickly and send the bill to the White House for the president's signature.

On July 23rd, the House passed by voice vote an amendment on human patenting offered by Dave Weldon (R-Fla.) as part of the Commerce-Justice-State appropriations bill (H.R. 2799).

In the early weeks of the 108th Congress, two Senate bills, S. 54 and S. 7, were introduced that embrace the "Greater Access to Affordable Pharmaceuticals Act of 2003" (GAAP), formerly known in the 107th Congress as S. 812

On October 24th the FDA published proposed regulations that affect implementation of the Hatch-Waxman law. These changes in part respond to recommendations in a July 2002 Federal Trade Commission (FTC) report and a Citizen Petition filed with the FDA by the FTC in May 2001.

How the industry can develop biodefense products.

In the wake of the September 11 terrorist attacks, BIO surveyed the industry and found that many biotech companies were already working on defense projects or developing technologies useful for both conventional health care and for defense against biological, chemical and radiological/nuclear agents.

Last week, the Senate Health, Education, Labor and Pensions (HELP) Committee marked-up legislation - The Edwards/Collins substitute to S. 812 - The "Greater Access to Affordable Pharmaceuticals Act of 2001" - that raises serious concerns for members of the Biotechnology Industry Organization (BIO).

BIO-IES urges national representatives of the United States and other nations to seek inclusion of specific references to industrial and environmental biotechnology in the implementation program resulting from the Johannesburg Summit, including national action plans.

The Earth Summit at Rio de Janeiro in 1992 established a vision of "Sustainable Development." Where development historically was based almost entirely on economic calculations, there would now be an environmental component as well.

HHS Addresses Many of BIO's Concerns In Proposing Changes to the HIPAA Privacy Regulation

"Some History Should be Repeated," by Carl B. Feldbaum, Science, Feb. 8, 2002. An excerpt appears below.

To Promote Public Health and National Security and to Fight Against Bioterrorism

The Biotechnology Industry Organization (BIO), in anticipation of possible debates on the changes to the Medicare reimbursement formula for currently covered drugs, has developed the following principles for consideration of various proposals. While we acknowledge that the current formula "Average Wholesale Price" (AWP) minus five percent may be changed, BIO urges Members of Congress to carefully consider the potential effects of various proposed changes to AWP on the quality of patient care and access to biotechnology products.

Biotechnology tools and techniques open new research avenues for discovering how healthy bodies work and what goes wrong when problems arise.

As people age they walk a minefield of life-threatening and debilitating diseases.